[Turner syndrome: a virtually certain indication for growth hormone treatment]
- PMID: 1448805
[Turner syndrome: a virtually certain indication for growth hormone treatment]
Abstract
Short stature is a feature in almost all cases with Turner syndrome. The etiology is unknown, but GH secretion appears to be normal. The treatment with anabolic steroids does not seem to increase final height. Oestrogens are needed for secondary sex characteristics, but should be given in a low dosage and at approximately 12-13 years of age, in order not to compromise final height. Growth hormone increases growth velocity and leads to an average gain of 5 cm in terms of final height. The addition of oxandrolone leads to an even higher growth rate, but final height is probably similar to that reached by growth hormone alone. The dosage, injection frequency, age and bone age at the start of therapy have influence on the efficacy. GH in the dosages given appears safe.
Similar articles
-
Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation and final height.Acta Paediatr. 1996 Dec;85(12):1408-14. Acta Paediatr. 1996. PMID: 9001649
-
Growth hormone therapy in Turner's syndrome: an update on final height. Genentech National Cooperative Study Group.Acta Paediatr Suppl. 1992 Sep;383:3-6; discussion 7. Acta Paediatr Suppl. 1992. PMID: 1458013 Clinical Trial.
-
[Possibilities to increase the efficacy of growth hormone therapy in Turner syndrome].Orv Hetil. 1997 Jun 8;138(23):1501-5. Orv Hetil. 1997. PMID: 9254366 Review. Hungarian.
-
Growth hormone therapy in Turner syndrome.Pediatr Endocrinol Rev. 2012 May;9 Suppl 2:723-4. Pediatr Endocrinol Rev. 2012. PMID: 22946284
-
Growth hormone therapy in Turner's syndrome.Ir Med J. 1992 Jun;85(2):68-9. Ir Med J. 1992. PMID: 1628947 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical